多西他赛联合卡培他滨治疗FOLFOX 方案失败晚期胃癌的临床观察.docVIP

精品论文 参考文献 多西他赛联合卡培他滨治疗FOLFOX 方案失败晚期胃癌的临床观察 西安一四一医院 710000 【摘 要】目的：观察多西他赛联合卡培他滨方案治疗FOLFOX方案(草酸铂+5-氟尿嘧啶/亚叶酸钙)失败晚期胃癌的疗效和不良反应。方法 27例FOLFOX方案失败的晚期胃癌患者, 应用多西他赛联合卡培他滨方案治疗2~6个周期。观察疗效。结果27例均可评价, 有效率为37%, 其中完全缓解1例, 部分缓解9例(33.3%), 稳定11例(40.7%), 进展7例(22.2%), 中位生存期10个月。不良反应主要为恶心呕吐、腹泻、骨髓抑制和肝功能损害, 但均为轻度。结论 多西他赛联合卡培他滨方案方案治疗FOLFOX方案失败的晚期胃癌有一定疗效, 不良反应可耐受, 值得临床推广应用。 【关键词】胃癌；多西他赛；卡培他滨 Clinical observation of Docetaxel in Combination with Capecitabine regimen in the treatment of gastric carcinoma with failed FOLFLX regimen ZHANG Li-xia Xi an 141 Hospital 【Abstract】Objective to observe the curative effect and adverse reactions of Docetaxel in Combination with Capecitabine regimen in the treatment of advanced gastric carcinoma with failed FOLFLX regimen (oxaliplatin+5-fluorouracil/calcium folinate). Methods There were 27 patients with advanced gastric carcinoma received failed FOLFOX regimen, and they all received Docetaxel in Combination with Capecitabine regimen for treatment for 2~6 period. Curative effect was observed. Results All the 27 cases could be evaluated, and their effective rate was 33.3%. There were 1 case of complete remission, 9 cases of partial remission (33.3%), 11 stable cases (40.7%), and 7 progressed cases (22.2%). The median survival time was 10 months. The main adverse reactions included nausea and emesis, diarrhea, myelosuppression, and liver function damage all at mild stage. Conclusion Docetaxel in Combination with Capecitabine regimen in the treatment of advanced gastric carcinoma w ith failed FOLFOX regimen has a certain effect and tolerable adverse reactions, and it is worthy of clinical promotion and application. 【Key words】Gastric carcinoma; Docetaxel；Capecitabine 【中图分类号】R737.9【文献标识码】A【文章编号】2096-0867（2016）-2-136-02 胃癌是全球最常见的肿瘤之一，对人类健康危害极大，发病率在全球肿瘤排位中位居第四，死亡率位居肿瘤相关死亡的第二位[1]，我国新发病例数占全球的42%。我国胃癌早期诊断率较低，约2/3患者在就诊时已处于中晚期，伴有局部浸润、淋巴结及远处转移和其它一些全身的并发症，中位生存期仅为7～9月，2年生存率小于10%。近几十年，在晚期胃癌的化疗方面，国内外学者们进行了大量临床试验研究，但至今并没有标准方案。FOLFOX方案耐受性较好,